Contact a rep button
contact a rep

stay connected!

Fill in the required fields to stay up to date with news and announcements about VPRIV.
*Required Field

One or more required fields are invalid.

Please review and submit this form again.

thank you!

You have been successfully signed up to receive
communications from Takeda

Click here to unsubscribe

VPRIV READY

ALISON — PATIENT PREFERENCE*

*Patient profiles for illustrative purposes only and do not depict actual patients

female patient

Alison was diagnosed with type 1 Gaucher disease when she was 22 years old, after experiencing moderate anemia and fatigue.1

After speaking with her doctor about risks and benefits of treatment, she and her doctor chose VPRIV. She was treated with VPRIV for several years at an infusion center and then switched to substrate reduction therapy (SRT) when it became available.

After some time on SRT, she elected to switch back to VPRIV and has remained on VPRIV since.

Alisonʼs career demands much of her time, so she now receives her 60-minute VPRIV infusion at home.2

consider
  • VPRIV has been evaluated during clinical trials in 73 adult patients (≥18 years)5
  • VPRIV is a 60-minute infusion taken once every other week, which may be administered at home under the supervision of a healthcare professional2

CLICK ON EACH PATIENT BELOW TO READ THEIR STORY:

These are hypothetical patient profiles intended to represent patients with type 1 Gaucher disease

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate VPRIV in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment.